# Official Journal C 144/2007

| | ISSN 1725-2423 |
| --- | --- |
| Official Journal
  of the European Union | C 144 |
| | |
| English edition | Information and Notices | Volume 5029 June 2007 |

ISSN 1725-2423

Official Journal

of the European Union

C 144

English edition

Information and Notices

Volume 5029 June 2007

---

| Notice No | Contents | page |
| --- | --- | --- |
| | I   Resolutions, recommendations, guidelines and opinions |
| | OPINIONS |
| | Council |
| 2007/C 144/01 | Notice for the attention of the persons, groups and entities on the list provided for in Article 2(3) of Council Regulation (EC) No 2580/2001 on specific restrictive measures directed against certain persons and entities with a view to combating terrorism (see Annex to Council Decision 2007/445/EC of 28 June 2007) | 1 |

Notice No

Contents

page

I   Resolutions, recommendations, guidelines and opinions

OPINIONS

Council

2007/C 144/01

Notice for the attention of the persons, groups and entities on the list provided for in Article 2(3) of Council Regulation (EC) No 2580/2001 on specific restrictive measures directed against certain persons and entities with a view to combating terrorism (see Annex to Council Decision 2007/445/EC of 28 June 2007)

1

| | II   Information |
| --- | --- |
| | INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES |
| | Commission |
| 2007/C 144/02 | Non-opposition to a notified concentration (Case COMP/M.4569 — GE/Abbott Diagnostics Division) (
  1
  ) | 2 |
| 2007/C 144/03 | Non-opposition to a notified concentration (Case COMP/M.4674 — KKR/Stefano Pessina/Alliance Boots) (
  1
  ) | 2 |
| 2007/C 144/04 | Non-opposition to a notified concentration (Case COMP/M.4599 — RWE Power/Carbon/JV) (
  1
  ) | 3 |

II   Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES

Commission

2007/C 144/02

Non-opposition to a notified concentration (Case COMP/M.4569 — GE/Abbott Diagnostics Division) (
  1
  )

1

2

2007/C 144/03

Non-opposition to a notified concentration (Case COMP/M.4674 — KKR/Stefano Pessina/Alliance Boots) (
  1
  )

1

2

2007/C 144/04

Non-opposition to a notified concentration (Case COMP/M.4599 — RWE Power/Carbon/JV) (
  1
  )

1

3

| | IV   Notices |
| --- | --- |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES |
| | Commission |
| 2007/C 144/05 | Euro exchange rates | 4 |
| 2007/C 144/06 | Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 May 2007 to 31 May 2007(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council) | 5 |
| 2007/C 144/07 | Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 May 2007 to 31 May 2007(Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC) | 11 |

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES

Commission

2007/C 144/05

Euro exchange rates

4

2007/C 144/06

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 May 2007 to 31 May 2007(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)

5

2007/C 144/07

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 May 2007 to 31 May 2007(Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC)

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC)

11

| | V   Announcements |
| --- | --- |
| | ADMINISTRATIVE PROCEDURES |
| | European Parliament |
| 2007/C 144/08 | Call for proposals (No VIII-2008/01) — Grants to political parties at European level | 22 |
| | PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMPETITION POLICY |
| | Commission |
| 2007/C 144/09 | Prior notification of a concentration (Case COMP/M.4688 — Nestlé/Gerber) (
  1
  ) | 25 |

V   Announcements

ADMINISTRATIVE PROCEDURES

European Parliament

2007/C 144/08

Call for proposals (No VIII-2008/01) — Grants to political parties at European level

22

PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMPETITION POLICY

Commission

2007/C 144/09

Prior notification of a concentration (Case COMP/M.4688 — Nestlé/Gerber) (
  1
  )

1

25

| | |
| --- | --- |
| | (1)   Text with EEA relevance |

---

(1)   Text with EEA relevance

1

| EN | |
| --- | --- |

EN

---

I Resolutions, recommendations, guidelines and opinions

OPINIONS

Council

| 29.6.2007 | EN | Official Journal of the European Union | C 144/1 |
| --- | --- | --- | --- |

29.6.2007

EN

Official Journal of the European Union

C 144/1

---

Notice for the attention of the persons, groups and entities on the list provided for in Article 2(3) of Council Regulation (EC) No 2580/2001 on specific restrictive measures directed against certain persons and entities with a view to combating terrorism (see Annex to Council Decision 2007/445/EC of 28 June 2007)

(2007/C 144/01)

The following information is brought to the attention of the persons, groups and entities listed in Council Decision 2007/445/EC of 28 June 2007 (1).

The Council of the European Union has determined that the reasons for including the persons, groups and entities that appear on the above-mentioned list of persons, groups and entities subject to the restrictive measures provided for under Council Regulation (EC) No 2580/2001 of 27 December 2001, on specific restrictive measures directed against certain persons and entities with a view to combating terrorism (2), are still valid. Consequently, the Council has decided to maintain those persons, groups and entities on the list.

Regulation (EC) No 2580/2001 provides for a freezing of all funds, other financial assets and economic resources belonging to the persons, groups and entities concerned and that no funds, other financial assets and economic resources may be made available to them, whether directly or indirectly.

The attention of the persons, groups and entities concerned is drawn to the possibility of making an application to the competent authorities of the relevant Member State(s) as listed in the Annex to the Regulation in order to obtain an authorisation to use frozen funds for essential needs or specific payments in accordance with Article 5(2) of that Regulation. An updated list of competent authorities is available on the web at the following address:

http://ec.europa.eu/comm/external_relations/cfsp/sanctions/measures.htm

The persons, groups and entities concerned may submit a request to obtain the Council's statement of reasons for maintaining them on the above-mentioned list (unless the statement of reasons has already been communicated to them), to the following address: Council of the European Union (Attn: CP 931 designations) rue de la Loi 175 B-1048 Brussels.

The persons, groups and entities concerned may submit at any time a request to the Council, together with any supporting documentation, that the decision to include and maintain them on the list should be reconsidered, to the address provided above. Such requests will be considered when they are received. In this respect, the attention of the persons, groups and entities concerned is drawn to the regular review by the Council of the list according to Article 1(6) of Common Position 2001/931/CFSP. In order for requests to be considered at the next review, they should be submitted within two months from the date of publication of this notice.

The attention of the persons, groups and entities concerned is also drawn to the possibility of challenging the Council's decision before the Court of First Instance of the European Communities, in accordance with the conditions laid down in Article 230(4) and (5) of the Treaty establishing the European Community.

---

(1)  OJ L 169, 29.6.2007.

(2)  OJ L 344, 28.12.2001, p. 70.

---

II Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES

Commission

| 29.6.2007 | EN | Official Journal of the European Union | C 144/2 |
| --- | --- | --- | --- |

29.6.2007

EN

Official Journal of the European Union

C 144/2

---

Non-opposition to a notified concentration

(Case COMP/M.4569 — GE/Abbott Diagnostics Division)

(Text with EEA relevance)

(2007/C 144/02)

On 24 April 2007, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website under document number 32007M4569. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu) |
| --- | --- |

—

in electronic form on the EUR-Lex website under document number 32007M4569. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu)

---

| 29.6.2007 | EN | Official Journal of the European Union | C 144/2 |
| --- | --- | --- | --- |

29.6.2007

EN

Official Journal of the European Union

C 144/2

---

Non-opposition to a notified concentration

(Case COMP/M.4674 — KKR/Stefano Pessina/Alliance Boots)

(Text with EEA relevance)

(2007/C 144/03)

On 18 June 2007, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website under document number 32007M4674. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu) |
| --- | --- |

—

in electronic form on the EUR-Lex website under document number 32007M4674. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu)

---

| 29.6.2007 | EN | Official Journal of the European Union | C 144/3 |
| --- | --- | --- | --- |

29.6.2007

EN

Official Journal of the European Union

C 144/3

---

Non-opposition to a notified concentration

(Case COMP/M.4599 — RWE Power/Carbon/JV)

(Text with EEA relevance)

(2007/C 144/04)

On 18 June 2007, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in German and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | from the Europa competition web site (http://ec.europa.eu/comm/competition/mergers/cases/). This web site provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

from the Europa competition web site (http://ec.europa.eu/comm/competition/mergers/cases/). This web site provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website under document number 32007M4599. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu) |
| --- | --- |

—

in electronic form on the EUR-Lex website under document number 32007M4599. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu)

---

IV Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES

Commission

| 29.6.2007 | EN | Official Journal of the European Union | C 144/4 |
| --- | --- | --- | --- |

29.6.2007

EN

Official Journal of the European Union

C 144/4

---

Euro exchange rates (1)

28 June 2007

(2007/C 144/05)

1 euro=

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,3467 |
| JPY | Japanese yen | 165,61 |
| DKK | Danish krone | 7,4425 |
| GBP | Pound sterling | 0,67215 |
| SEK | Swedish krona | 9,2415 |
| CHF | Swiss franc | 1,6544 |
| ISK | Iceland króna | 84,1 |
| NOK | Norwegian krone | 7,952 |
| BGN | Bulgarian lev | 1,9558 |
| CYP | Cyprus pound | 0,5837 |
| CZK | Czech koruna | 28,633 |
| EEK | Estonian kroon | 15,6466 |
| HUF | Hungarian forint | 247,44 |
| LTL | Lithuanian litas | 3,4528 |
| LVL | Latvian lats | 0,6962 |
| MTL | Maltese lira | 0,4293 |
| PLN | Polish zloty | 3,782 |
| RON | Romanian leu | 3,1666 |
| SKK | Slovak koruna | 33,832 |
| TRY | Turkish lira | 1,7796 |
| AUD | Australian dollar | 1,5918 |
| CAD | Canadian dollar | 1,4293 |
| HKD | Hong Kong dollar | 10,5264 |
| NZD | New Zealand dollar | 1,7513 |
| SGD | Singapore dollar | 2,0649 |
| KRW | South Korean won | 1 248,19 |
| ZAR | South African rand | 9,572 |
| CNY | Chinese yuan renminbi | 10,2553 |
| HRK | Croatian kuna | 7,3042 |
| IDR | Indonesian rupiah | 12 224,67 |
| MYR | Malaysian ringgit | 4,6683 |
| PHP | Philippine peso | 62,42 |
| RUB | Russian rouble | 34,742 |
| THB | Thai baht | 42,859 |

Currency

Exchange rate

USD

US dollar

1,3467

JPY

Japanese yen

165,61

DKK

Danish krone

7,4425

GBP

Pound sterling

0,67215

SEK

Swedish krona

9,2415

CHF

Swiss franc

1,6544

ISK

Iceland króna

84,1

NOK

Norwegian krone

7,952

BGN

Bulgarian lev

1,9558

CYP

Cyprus pound

0,5837

CZK

Czech koruna

28,633

EEK

Estonian kroon

15,6466

HUF

Hungarian forint

247,44

LTL

Lithuanian litas

3,4528

LVL

Latvian lats

0,6962

MTL

Maltese lira

0,4293

PLN

Polish zloty

3,782

RON

Romanian leu

3,1666

SKK

Slovak koruna

33,832

TRY

Turkish lira

1,7796

AUD

Australian dollar

1,5918

CAD

Canadian dollar

1,4293

HKD

Hong Kong dollar

10,5264

NZD

New Zealand dollar

1,7513

SGD

Singapore dollar

2,0649

KRW

South Korean won

1 248,19

ZAR

South African rand

9,572

CNY

Chinese yuan renminbi

10,2553

HRK

Croatian kuna

7,3042

IDR

Indonesian rupiah

12 224,67

MYR

Malaysian ringgit

4,6683

PHP

Philippine peso

62,42

RUB

Russian rouble

34,742

THB

Thai baht

42,859

---

(1)

Source: reference exchange rate published by the ECB.

---

| 29.6.2007 | EN | Official Journal of the European Union | C 144/5 |
| --- | --- | --- | --- |

29.6.2007

EN

Official Journal of the European Union

C 144/5

---

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 May 2007 to 31 May 2007

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1))

(2007/C 144/06)

—   Issuing of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

| Date of the decision | Name of the medicinal product | INN
  (International Non-Proprietary Name) | Holder of the marketing authorization | Number of the entry in the Community Register | Pharmaceutical form | ATC code
  (Anatomical Therapeutic Chemical Code) | Date of notification |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 2.5.2007 | Focetria | A/Viet Nam/1194/2004 (H5N1) virus surface inactivated antigen | Novartis Vaccines and Diagnostics S.r.l. |
| Via Fiorentina, 1 |
| I-53100 Siena |

Date of the decision

Name of the medicinal product

INN

(International Non-Proprietary Name)

Holder of the marketing authorization

Number of the entry in the Community Register

Pharmaceutical form

ATC code

(Anatomical Therapeutic Chemical Code)

Date of notification

2.5.2007

Focetria

A/Viet Nam/1194/2004 (H5N1) virus surface inactivated antigen

Novartis Vaccines and Diagnostics S.r.l.

Via Fiorentina, 1

I-53100 Siena

EU/1/07/385/001-004

Suspension for injection

J07BB02

4.5.2007

21.5.2007

ORENCIA

abatacept

| Bristol-Myers Squibb Pharma EEIG |
| --- |
| Uxbridge Business Park |
| Sanderson Road |
| Uxbridge UB8 1DH |
| United Kingdom |

Bristol-Myers Squibb Pharma EEIG

Uxbridge Business Park

Sanderson Road

Uxbridge UB8 1DH

United Kingdom

EU/1/07/389/001-003

Powder for concentrate for solution for infusion

L04AA24

23.5.2007

24.5.2007

Altargo

retapamulin

| Glaxo Group Ltd. |
| --- |
| Greenford Road |
| Greenford |
| Middlesex UB6 0NN |
| United Kingdom |

Glaxo Group Ltd.

Greenford Road

Greenford

Middlesex UB6 0NN

United Kingdom

EU/1/07/390/001-004

Ointment

D06AX13

29.5.2007

—   Issuing of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Rejected

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 22.5.2007 | Mycograb | NeuTec Pharma plc |
| Central Manchester & Manchester Children's Hospital NHS Trust |
| Oxford Rd |
| Manchester M13 9WL |
| United Kingdom |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

22.5.2007

Mycograb

NeuTec Pharma plc

Central Manchester & Manchester Children's Hospital NHS Trust

Oxford Rd

Manchester M13 9WL

United Kingdom

—

29.5.2007

—   Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 2.5.2007 | Aranesp | Amgen Europe B.V. |
| Minervum 7061 |
| 4817 ZK Breda |
| Nederland |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

2.5.2007

Aranesp

Amgen Europe B.V.

Minervum 7061

4817 ZK Breda

Nederland

EU/1/01/185/001-073

4.5.2007

2.5.2007

Liprolog

| Eli Lilly Nederland B.V. |
| --- |
| Grootslag 1-5 |
| 3991 RA Houten |
| Nederland |

Eli Lilly Nederland B.V.

Grootslag 1-5

3991 RA Houten

Nederland

EU/1/01/195/001-015

4.5.2007

2.5.2007

BeneFIX

| Wyeth Europa Ltd. |
| --- |
| Huntercombe Lane South |
| Taplow |
| Maidenhead |
| Berkshire SL6 0PH |
| United Kingdom |

Wyeth Europa Ltd.

Huntercombe Lane South

Taplow

Maidenhead

Berkshire SL6 0PH

United Kingdom

EU/1/97/047/001-003

4.5.2007

2.5.2007

Vfend

| Pfizer Limited |
| --- |
| Ramsgate Road |
| Sandwich |
| Kent CT13 9NJ |
| United Kingdom |

Pfizer Limited

Ramsgate Road

Sandwich

Kent CT13 9NJ

United Kingdom

EU/1/02/212/001-026

4.5.2007

2.5.2007

Nespo

| Dompé Biotec S.p.A. |
| --- |
| Via San Martino, 12 |
| I-20122 Milano |

Dompé Biotec S.p.A.

Via San Martino, 12

I-20122 Milano

EU/1/01/184/001-073

4.5.2007

2.5.2007

Invirase

| Roche Registration Limited |
| --- |
| 6 Falcon Way |
| Shire Park |
| Welwyn Garden City AL7 1TW |
| United Kingdom |

Roche Registration Limited

6 Falcon Way

Shire Park

Welwyn Garden City AL7 1TW

United Kingdom

EU/1/96/026/001-002

4.5.2007

2.5.2007

Norvir

| Abbott laboratories Ltd |
| --- |
| Queenborough |
| Kent ME11 5EL |
| United Kingdom |

Abbott laboratories Ltd

Queenborough

Kent ME11 5EL

United Kingdom

EU/1/96/016/001

EU/1/96/016/003-004

4.5.2007

2.5.2007

Viramune

| Boehringer Ingelheim International GmbH |
| --- |
| Binger Straße 173 |
| D-55216 Ingelheim am Rhein |

Boehringer Ingelheim International GmbH

Binger Straße 173

D-55216 Ingelheim am Rhein

EU/1/97/055/001-003

4.5.2007

2.5.2007

Viread

| Gilead Sciences International Limited |
| --- |
| Cambridge CB21 6GT |
| United Kingdom |

Gilead Sciences International Limited

Cambridge CB21 6GT

United Kingdom

EU/1/01/200/001

4.5.2007

2.5.2007

Osigraft

| Howmedica International S. de R.L. |
| --- |
| Division of Stryker Corporation |
| Raheen Industrial Estate |
| Raheen |
| Limerick |
| Ireland |

Howmedica International S. de R.L.

Division of Stryker Corporation

Raheen Industrial Estate

Raheen

Limerick

Ireland

EU/1/01/179/001

4.5.2007

2.5.2007

Sustiva

| Bristol-Myers Squibb Pharma EEIG |
| --- |
| Uxbridge Business Park |
| Sanderson Road |
| Uxbridge UD8 1DH |
| United Kingdom |

Bristol-Myers Squibb Pharma EEIG

Uxbridge Business Park

Sanderson Road

Uxbridge UD8 1DH

United Kingdom

EU/1/99/110/001-009

4.5.2007

2.5.2007

Stocrin

| Merck Sharp & Dohme Ltd |
| --- |
| Hertford Road |
| Hoddesdon |
| Hertfordshire EN11 9BU |
| United Kingdom |

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

EU/1/99/111/001-011

4.5.2007

3.5.2007

Protopy

| Astellas Pharma GmbH |
| --- |
| Neumarkter Str. 61 |
| D-81673 München |

Astellas Pharma GmbH

Neumarkter Str. 61

D-81673 München

EU/1/02/202/001-006

7.5.2007

3.5.2007

Crixivan

| Merck Sharp & Dohme Ltd |
| --- |
| Hertford Road |
| Hoddesdon |
| Hertfordshire EN11 9BU |
| United Kingdom |

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

EU/1/96/024/001-005

EU/1/96/024/007-008

EU/1/96/024/010

8.5.2007

3.5.2007

Protopic

| Astellas Pharma GmbH |
| --- |
| Neumarkter Str. 61 |
| D-81673 München |

Astellas Pharma GmbH

Neumarkter Str. 61

D-81673 München

EU/1/02/201/001-006

7.5.2007

3.5.2007

Infanrix Hexa

| GlaxoSmithKline Biologicals s.a. |
| --- |
| rue de l'Institut 89 |
| B-1330 Rixensart |

GlaxoSmithKline Biologicals s.a.

rue de l'Institut 89

B-1330 Rixensart

EU/1/00/152/001-018

7.5.2007

3.5.2007

Infanrix Penta

| GlaxoSmithKline Biologicals s.a. |
| --- |
| rue de l'Institut 89 |
| B-1330 Rixensart |

GlaxoSmithKline Biologicals s.a.

rue de l'Institut 89

B-1330 Rixensart

EU/1/00/153/001-010

7.5.2007

3.5.2007

Humalog

| Eli Lilly Nederland B.V. |
| --- |
| Grootslag 1-5 |
| 3991 RA Houten |
| Nederland |

Eli Lilly Nederland B.V.

Grootslag 1-5

3991 RA Houten

Nederland

EU/1/96/007/002

EU/1/96/007/004-006

EU/1/96/007/008

EU/1/96/007/010-011

EU/1/96/007/015-021

EU/1/96/007/023-030

7.5.2007

11.5.2007

Prialt

| Eisai Limited |
| --- |
| 3, Shortlands |
| London W6 8EE |
| United Kingdom |

Eisai Limited

3, Shortlands

London W6 8EE

United Kingdom

EU/1/04/302/001-004

15.5.2007

14.5.2007

PritorPlus

| Bayer HealthCare AG |
| --- |
| D-51368 Leverkusen |

Bayer HealthCare AG

D-51368 Leverkusen

EU/1/02/215/001-014

16.5.2007

14.5.2007

Hepsera

| Gilead Sciences International Limited |
| --- |
| Granta Park Abington |
| Cambridge CB1 6GT |
| United Kingdom |

Gilead Sciences International Limited

Granta Park Abington

Cambridge CB1 6GT

United Kingdom

EU/1/03/251/001-002

16.5.2007

14.5.2007

Humira

| Abbott laboratories Ltd |
| --- |
| Queenborough |
| Kent ME11 5EL |
| United Kingdom |

Abbott laboratories Ltd

Queenborough

Kent ME11 5EL

United Kingdom

EU/1/03/256/001-010

16.5.2007

14.5.2007

Trudexa

| Abbott laboratories Ltd |
| --- |
| Queenborough |
| Kent ME11 5EL |
| United Kingdom |

Abbott laboratories Ltd

Queenborough

Kent ME11 5EL

United Kingdom

EU/1/03/257/001-010

16.5.2007

15.5.2007

Omnitrope

| Sandoz GmbH |
| --- |
| Biochemiestraße 10 |
| A-Kundl 6250 |

Sandoz GmbH

Biochemiestraße 10

A-Kundl 6250

EU/1/06/332/001-006

18.5.2007

15.5.2007

Iscover

| Bristol-Myers Squibb Pharma EEIG |
| --- |
| Uxbridge Business Park |
| Sanderson Road |
| Uxbridge UD8 1DH |
| United Kingdom |

Bristol-Myers Squibb Pharma EEIG

Uxbridge Business Park

Sanderson Road

Uxbridge UD8 1DH

United Kingdom

EU/1/98/070/001a–006a

EU/1/98/070/001b-006b

17.5.2007

15.5.2007

Plavix

| Sanofi Pharma Bristol-Myers Squibb SNC |
| --- |
| 174, avenue de France |
| F-75013 Paris |

Sanofi Pharma Bristol-Myers Squibb SNC

174, avenue de France

F-75013 Paris

EU/1/98/069/001a-006a

EU/1/98/069/001b-006b

21.5.2007

15.5.2007

Xagrid

| Shire Pharmaceutical Contracts Ltd |
| --- |
| Hampshire International Business Park |
| Chineham |
| Basingstoke |
| Hampshire RG24 8EP |
| United Kingdom |

Shire Pharmaceutical Contracts Ltd

Hampshire International Business Park

Chineham

Basingstoke

Hampshire RG24 8EP

United Kingdom

EU/1/04/295/001

17.5.2007

22.5.2007

Thelin

| Encysive (UK) Limited |
| --- |
| Alder Castle House |
| 10 Noble Street |
| London EC2V 7QJ |
| United Kingdom |

Encysive (UK) Limited

Alder Castle House

10 Noble Street

London EC2V 7QJ

United Kingdom

EU/1/06/353/001-005

25.5.2007

22.5.2007

Zavesca

| Actelion Registration Ltd |
| --- |
| BSI Building 13th Floor |
| 389 Chiswick High Road |
| London W4 4AL |
| United Kingdom |

Actelion Registration Ltd

BSI Building 13th Floor

389 Chiswick High Road

London W4 4AL

United Kingdom

EU/1/02/238/001

25.5.2007

22.5.2007

Teslascan

| GE Healthcare AS |
| --- |
| Nycoveien 1-2 |
| P.O. Box 4220 Nydalen |
| N-0401 Oslo |

GE Healthcare AS

Nycoveien 1-2

P.O. Box 4220 Nydalen

N-0401 Oslo

EU/1/97/040/001-002

25.5.2007

22.5.2007

Opatanol

| Alcon Laboratories (UK) Ltd. |
| --- |
| Pentagon Park |
| Boundary Way |
| Hemel Hempstead |
| Herts HP2 7UD |
| United Kingdom |

Alcon Laboratories (UK) Ltd.

Pentagon Park

Boundary Way

Hemel Hempstead

Herts HP2 7UD

United Kingdom

EU/1/02/217/001-002

24.5.2007

30.5.2007

Xolair

| Novartis Europharm Limited |
| --- |
| Wimblehurst Road |
| Horsham |
| West Sussex RH12 5AB |
| United Kingdom |

Novartis Europharm Limited

Wimblehurst Road

Horsham

West Sussex RH12 5AB

United Kingdom

EU/1/05/319/001-004

1.6.2007

30.5.2007

Caelyx

| Schering Plough Europe |
| --- |
| rue de Stalle, 73 |
| B-1180 Bruxelles |
| Stallestraat, 73 |
| B-1180 Brussel |

Schering Plough Europe

rue de Stalle, 73

B-1180 Bruxelles

Stallestraat, 73

B-1180 Brussel

EU/1/96/011/001-004

1.6.2007

30.5.2007

Ventavis

| Bayer Schering Pharma AG |
| --- |
| Müllerstraße 170-178 |
| D-13342 Berlin |

Bayer Schering Pharma AG

Müllerstraße 170-178

D-13342 Berlin

EU/1/03/255/001-005

1.6.2007

30.5.2007

Remicade

| Centocor B.V. |
| --- |
| Einsteinweg 101 |
| 2333 CB Leiden |
| Nederland |

Centocor B.V.

Einsteinweg 101

2333 CB Leiden

Nederland

EU/1/99/116/001-003

1.6.2007

30.5.2007

LeukoScan

| Immunomedics GmbH |
| --- |
| Otto-Röhm-Straße 69 |
| D-64293 Darmstadt |

Immunomedics GmbH

Otto-Röhm-Straße 69

D-64293 Darmstadt

EU/1/97/032/001

1.6.2007

30.5.2007

Ziagen

| Glaxo Group Ltd. |
| --- |
| Greenford Road |
| Greenford |
| Middlesex UB6 0NN |
| United Kingdom |

Glaxo Group Ltd.

Greenford Road

Greenford

Middlesex UB6 0NN

United Kingdom

EU/1/99/112/001-002

1.6.2007

30.5.2007

Kivexa

| Glaxo Group Ltd. |
| --- |
| Greenford Road |
| Greenford |
| Middlesex UB6 0NN |
| United Kingdom |

Glaxo Group Ltd.

Greenford Road

Greenford

Middlesex UB6 0NN

United Kingdom

EU/1/04/298/001-002

1.6.2007

30.5.2007

AVANDIA

| SmithKline Beecham plc |
| --- |
| 980 Great West Road |
| Brentford |
| Middlesex TW8 9GS |
| United Kingdom |

SmithKline Beecham plc

980 Great West Road

Brentford

Middlesex TW8 9GS

United Kingdom

EU/1/00/137/002-018

1.6.2007

30.5.2007

Viramune

| Boehringer Ingelheim International GmbH |
| --- |
| Binger Straße 173 |
| D-55216 Ingelheim am Rhein |

Boehringer Ingelheim International GmbH

Binger Straße 173

D-55216 Ingelheim am Rhein

EU/1/97/055/001-003

1.6.2007

30.5.2007

Avaglim

| SmithKline Beecham plc |
| --- |
| 980 Great West Road |
| Brentford |
| Middlesex TW8 9GS |
| United Kingdom |

SmithKline Beecham plc

980 Great West Road

Brentford

Middlesex TW8 9GS

United Kingdom

EU/1/06/349/001-010

1.6.2007

31.5.2007

Ketek

| Aventis Pharma S.A. |
| --- |
| 20, avenue Raymond Aron |
| F-92160 Antony |

Aventis Pharma S.A.

20, avenue Raymond Aron

F-92160 Antony

EU/1/01/191/001-005

4.6.2007

31.5.2007

Levviax

| Aventis Pharma S.A. |
| --- |
| 20, avenue Raymond Aron |
| F-92160 Antony |

Aventis Pharma S.A.

20, avenue Raymond Aron

F-92160 Antony

EU/1/01/192/001-005

5.6.2007

—   Issuing of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

| Date of the decision | Name of the medicinal product | INN
  (International Non-Proprietary Name) | Holder of the marketing authorization | Number of the entry in the Community Register | Pharmaceutical form | ATC code
  (Anatomical Therapeutic Chemical Code) | Date of notification |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 14.5.2007 | Nobilis Influenza H7N1 | Inactivated whole avian influenza virus antigen of H7N1 subtype (strain, A/CK/Italy/473/99), inducing an HI titre of ≥ 6,0 log2 as tested according to the potency test. | Intervet International B.V. | EU/2/07/073/001-004 | Emulsion for injection | QI01AA23 | 16.5.2007 |

Date of the decision

Name of the medicinal product

INN

(International Non-Proprietary Name)

Holder of the marketing authorization

Number of the entry in the Community Register

Pharmaceutical form

ATC code

(Anatomical Therapeutic Chemical Code)

Date of notification

14.5.2007

Nobilis Influenza H7N1

Inactivated whole avian influenza virus antigen of H7N1 subtype (strain, A/CK/Italy/473/99), inducing an HI titre of ≥ 6,0 log2 as tested according to the potency test.

Intervet International B.V.

EU/2/07/073/001-004

Emulsion for injection

QI01AA23

16.5.2007

—   Modification of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 15.5.2007 | METACAM | Boehringer Ingelheim Vetmedica GmbH |
| D-55216 Ingelheim am Rhein |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

15.5.2007

METACAM

Boehringer Ingelheim Vetmedica GmbH

D-55216 Ingelheim am Rhein

EU/2/97/004/007-008

EU/2/97/004/014-015

EU/2/97/004/027-028

18.5.2007

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

| The European Medicines Agency |
| --- |
| 7, Westferry Circus |
| Canary Wharf |
| London E14 4HB |
| United Kingdom |

The European Medicines Agency

7, Westferry Circus

Canary Wharf

London E14 4HB

United Kingdom

---

(1)  OJ L 136 of 30 April 2004, page 1

---

| 29.6.2007 | EN | Official Journal of the European Union | C 144/11 |
| --- | --- | --- | --- |

29.6.2007

EN

Official Journal of the European Union

C 144/11

---

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 May 2007 to 31 May 2007

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC (1) or Article 38 of Directive 2001/82/EC (2))

(2007/C 144/07)

—   Issuing, maintenance or modification of a national marketing authorisation

| Date of the decision | Name(s) of the medicinal product | Holder(s) of the marketing authorization | Member State concerned | Date of notification |
| --- | --- | --- | --- | --- |
| 22.5.2007 | Doxyprex | See Annex I | See Annex I | 24.5.2007 |
| 22.5.2007 | Thelin | This Decision is addressed to the Member States | This Decision is addressed to the Member States | 24.5.2007 |
| 29.5.2007 | Xefo | See Annex II | See Annex II | 30.5.2007 |
| 30.5.2007 | Remicade | This Decision is addressed to the Member States | This Decision is addressed to the Member States | 31.5.2007 |

Date of the decision

Name(s) of the medicinal product

Holder(s) of the marketing authorization

Member State concerned

Date of notification

22.5.2007

Doxyprex

See Annex I

See Annex I

24.5.2007

22.5.2007

Thelin

This Decision is addressed to the Member States

This Decision is addressed to the Member States

24.5.2007

29.5.2007

Xefo

See Annex II

See Annex II

30.5.2007

30.5.2007

Remicade

This Decision is addressed to the Member States

This Decision is addressed to the Member States

31.5.2007

—   Suspension of a national marketing authorization

| Date of the decision | Name(s) of the medicinal product | Holder(s) of the marketing authorization | Member State concerned | Date of notification |
| --- | --- | --- | --- | --- |
| 2.5.2007 | Alendros 70 | See Annex III | See Annex III | 4.5.2007 |

Date of the decision

Name(s) of the medicinal product

Holder(s) of the marketing authorization

Member State concerned

Date of notification

2.5.2007

Alendros 70

See Annex III

See Annex III

4.5.2007

---

(1)  OJ L 311, 28.11.2001, p. 67.

(2)  OJ L 311, 28.11.2001, p. 1.

---

ANNEX I

NAME, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ANIMAL SPECIES, ROUTES OF ADMINISTRATION, AND MARKETING AUTHORISATION HOLDER

| Member State | Applicant or Marketing Authorisation Holder | Product invented name | Pharmaceutical form | Strength | Animal species | Frequency and route of administration | Recommended dose |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Belgium, Czech Republic, Germany, Greece, Spain, France, Italy, The Netherlands, Poland, Portugal and Slovakia | Industrial Veterinaria, S.A. |
| Esmeralda, 19-4o |
| E-08950 Esplugues de Llobregat (Barcelona) |

Member State

Applicant or Marketing Authorisation Holder

Product invented name

Pharmaceutical form

Strength

Animal species

Frequency and route of administration

Recommended dose

Belgium, Czech Republic, Germany, Greece, Spain, France, Italy, The Netherlands, Poland, Portugal and Slovakia

Industrial Veterinaria, S.A.

Esmeralda, 19-4o

E-08950 Esplugues de Llobregat (Barcelona)

DOXYPREX

Premix

100 mg/g

Pigs (after weaning)

In feed use

10 mg/kg .bw

---

ANNEX II

LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES

| Member State | Marketing Authorisation Holder | Invented name | Strength | Pharmaceutical Form | Route of administration | Content |
| --- | --- | --- | --- | --- | --- | --- |
| Austria | Nycomed Austria GmbH |
| St. Peter Straße 25 |
| A-4020 Linz |

Member State

Marketing Authorisation Holder

Invented name

Strength

Pharmaceutical Form

Route of administration

Content

Austria

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Artok

4 mg

Film-coated tablet

Oral

4 mg

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Lornox

4 mg

Film-coated tablet

Oral

4 mg

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

4 mg

Film-coated tablet

Oral

4 mg

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Artok

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo Rapid

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Lornoxicam ‘Nycomed’

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

Belgium

| Nycomed Christians |
| --- |
| Gentsesteenweg 615 |
| B-1080 Brussel |

Nycomed Christians

Gentsesteenweg 615

B-1080 Brussel

Xefo

4 mg

Film-coated tablet

Oral

4 mg

| Nycomed Christians |
| --- |
| Gentsesteenweg 615 |
| B-1080 Brussel |

Nycomed Christians

Gentsesteenweg 615

B-1080 Brussel

Xefo

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Christians |
| --- |
| Gentsesteenweg 615 |
| B-1080 Brussel |

Nycomed Christians

Gentsesteenweg 615

B-1080 Brussel

Xefo Acute

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Christians |
| --- |
| Gentsesteenweg 615 |
| B-1080 Brussel |

Nycomed Christians

Gentsesteenweg 615

B-1080 Brussel

Xefo

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

Bulgaria

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

4 mg

Film-coated tablet

Oral

4 mg

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

Czech Republic

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

4 mg

Film-coated tablet

Oral

4 mg

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

Denmark

| Nycomed Danmark ApS |
| --- |
| Langebjerg 1 |
| DK-4000 Roskilde |

Nycomed Danmark ApS

Langebjerg 1

DK-4000 Roskilde

Lornoxicam ‘Nycomed’

4 mg

Film-coated tablet

Oral

4 mg

| Nycomed Danmark ApS |
| --- |
| Langebjerg 1 |
| DK-4000 Roskilde |

Nycomed Danmark ApS

Langebjerg 1

DK-4000 Roskilde

Xefo

4 mg

Film-coated tablet

Oral

4 mg

| Nycomed Danmark ApS |
| --- |
| Langebjerg 1 |
| DK-4000 Roskilde |

Nycomed Danmark ApS

Langebjerg 1

DK-4000 Roskilde

Lornoxicam ‘Nycomed’

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Danmark ApS |
| --- |
| Langebjerg 1 |
| DK-4000 Roskilde |

Nycomed Danmark ApS

Langebjerg 1

DK-4000 Roskilde

Xefo

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Danmark ApS |
| --- |
| Langebjerg 1 |
| DK-4000 Roskilde |

Nycomed Danmark ApS

Langebjerg 1

DK-4000 Roskilde

Xefo Rapid

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Danmark ApS |
| --- |
| Langebjerg 1 |
| DK-4000 Roskilde |

Nycomed Danmark ApS

Langebjerg 1

DK-4000 Roskilde

Lornoxicam ‘Nycomed’

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

| Nycomed Danmark ApS |
| --- |
| Langebjerg 1 |
| DK-4000 Roskilde |

Nycomed Danmark ApS

Langebjerg 1

DK-4000 Roskilde

Xefo

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

Estonia

| Nycomed SEFA |
| --- |
| Jaama 55B |
| EE-63308 Pölva |

Nycomed SEFA

Jaama 55B

EE-63308 Pölva

Xefo

4 mg

Film-coated tablet

Oral

4 mg

| Nycomed SEFA |
| --- |
| Jaama 55B |
| EE-63308 Pölva |

Nycomed SEFA

Jaama 55B

EE-63308 Pölva

Xefo

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed SEFA |
| --- |
| Jaama 55B |
| EE-63308 Pölva |

Nycomed SEFA

Jaama 55B

EE-63308 Pölva

Xefo Rapid

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed SEFA |
| --- |
| Jaama 55B |
| EE-63308 Pölva |

Nycomed SEFA

Jaama 55B

EE-63308 Pölva

Xefo

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

Germany

| Nycomed Danmark ApS |
| --- |
| Langebjerg 1 |
| DK-4000 Roskilde |

Nycomed Danmark ApS

Langebjerg 1

DK-4000 Roskilde

Lornoxicam ‘Nycomed’

4 mg

Film-coated tablet

Oral

4 mg

| Nycomed Pharma GmbH |
| --- |
| Edisonstraße 16 |
| D-85716 Unterschleissheim |

Nycomed Pharma GmbH

Edisonstraße 16

D-85716 Unterschleissheim

Telos

4 mg

Film-coated tablet

Oral

4 mg

| Nycomed Danmark ApS |
| --- |
| Langebjerg 1 |
| DK-4000 Roskilde |

Nycomed Danmark ApS

Langebjerg 1

DK-4000 Roskilde

Lornoxicam ‘Nycomed’

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Pharma GmbH |
| --- |
| Edisonstraße 16 |
| D-85716 Unterschleissheim |

Nycomed Pharma GmbH

Edisonstraße 16

D-85716 Unterschleissheim

Telos

8 mg

Film-coated tablet

Oral

8 mg

Greece

| Nycomed Hellas S.A. |
| --- |
| Λεωφ. Κηφισίας 196 |
| GR-152 31 Αθήνα |

Nycomed Hellas S.A.

Λεωφ. Κηφισίας 196

GR-152 31 Αθήνα

Xefo

4 mg

Film-coated tablet

Oral

4 mg

| Nycomed Hellas S.A. |
| --- |
| Λεωφ. Κηφισίας 196 |
| GR-152 31 Αθήνα |

Nycomed Hellas S.A.

Λεωφ. Κηφισίας 196

GR-152 31 Αθήνα

Xefo

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Hellas S.A. |
| --- |
| Λεωφ. Κηφισίας 196 |
| GR-152 31 Αθήνα |

Nycomed Hellas S.A.

Λεωφ. Κηφισίας 196

GR-152 31 Αθήνα

Xefo Rapid

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Hellas S.A. |
| --- |
| Λεωφ. Κηφισίας 196 |
| GR-152 31 Αθήνα |

Nycomed Hellas S.A.

Λεωφ. Κηφισίας 196

GR-152 31 Αθήνα

Xefo

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

Hungary

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

4 mg

Film-coated tablet

Oral

4 mg

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

Italy

| Nycomed Italy S.r.l. |
| --- |
| Via Carducci 125 |
| Edificio A |
| I-20099 Sesto San Giovanni |

Nycomed Italy S.r.l.

Via Carducci 125

Edificio A

I-20099 Sesto San Giovanni

Taigalor

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Italy S.r.l. |
| --- |
| Via Carducci 125 |
| Edificio A |
| I-20099 Sesto San Giovanni |

Nycomed Italy S.r.l.

Via Carducci 125

Edificio A

I-20099 Sesto San Giovanni

Xefo

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Italy S.r.l. |
| --- |
| Via Carducci 125 |
| Edificio A |
| I-20099 Sesto San Giovanni |

Nycomed Italy S.r.l.

Via Carducci 125

Edificio A

I-20099 Sesto San Giovanni

Taigalor

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

| Nycomed Italy S.r.l. |
| --- |
| Via Carducci 125 |
| Edificio A |
| I-20099 Sesto San Giovanni |

Nycomed Italy S.r.l.

Via Carducci 125

Edificio A

I-20099 Sesto San Giovanni

Xefo

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

Latvia

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

4 mg

Film-coated tablet

Oral

4 mg

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed SEFA |
| --- |
| Jaama 55B |
| EE-63308 Pölva |

Nycomed SEFA

Jaama 55B

EE-63308 Pölva

Xefo Rapid

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

Lithuania

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

4 mg

Film-coated tablet

Oral

4 mg

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed SEFA |
| --- |
| Jaama 55B |
| EE-63308 Pölva |

Nycomed SEFA

Jaama 55B

EE-63308 Pölva

Xefo Rapid

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

Luxembourg

| Nycomed Christians |
| --- |
| Gentsesteenweg 615 |
| B-1080 Brussel |

Nycomed Christians

Gentsesteenweg 615

B-1080 Brussel

Xefo

4 mg

Film-coated tablet

Oral

4 mg

| Nycomed Christians |
| --- |
| Gentsesteenweg 615 |
| B-1080 Brussel |

Nycomed Christians

Gentsesteenweg 615

B-1080 Brussel

Xefo

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Christians |
| --- |
| Gentsesteenweg 615 |
| B-1080 Brussel |

Nycomed Christians

Gentsesteenweg 615

B-1080 Brussel

Xefo Acute

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Christians |
| --- |
| Gentsesteenweg 615 |
| B-1080 Brussel |

Nycomed Christians

Gentsesteenweg 615

B-1080 Brussel

Xefo

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

Portugal

| Euro-Labor SA |
| --- |
| Rua Alfredo da Silva n.o 16 |
| P-2610-016 Amadora |

Euro-Labor SA

Rua Alfredo da Silva n.o 16

P-2610-016 Amadora

Acabel

4 mg

Film-coated tablet

Oral

4 mg

| Euro-Labor SA |
| --- |
| Rua Alfredo da Silva n.o 16 |
| P-2610-016 Amadora |

Euro-Labor SA

Rua Alfredo da Silva n.o 16

P-2610-016 Amadora

Bosporon

4 mg

Film-coated tablet

Oral

4 mg

| Euro-Labor SA |
| --- |
| Rua Alfredo da Silva n.o 16 |
| P-2610-016 Amadora |

Euro-Labor SA

Rua Alfredo da Silva n.o 16

P-2610-016 Amadora

Acabel

8 mg

Film-coated tablet

Oral

8 mg

| Euro-Labor SA |
| --- |
| Rua Alfredo da Silva n.o 16 |
| P-2610-016 Amadora |

Euro-Labor SA

Rua Alfredo da Silva n.o 16

P-2610-016 Amadora

Bosporon

8 mg

Film-coated tablet

Oral

8 mg

| Euro-Labor SA |
| --- |
| Rua Alfredo da Silva n.o 16 |
| P-2610-016 Amadora |

Euro-Labor SA

Rua Alfredo da Silva n.o 16

P-2610-016 Amadora

Acabel Rapid

8 mg

Film-coated tablet

Oral

8 mg

| Euro-Labor SA |
| --- |
| Rua Alfredo da Silva n.o 16 |
| P-2610-016 Amadora |

Euro-Labor SA

Rua Alfredo da Silva n.o 16

P-2610-016 Amadora

Bosporon Rapid

8 mg

Film-coated tablet

Oral

8 mg

| Euro-Labor SA |
| --- |
| Rua Alfredo da Silva n.o 16 |
| P-2610-016 Amadora |

Euro-Labor SA

Rua Alfredo da Silva n.o 16

P-2610-016 Amadora

Acabel

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

| Euro-Labor SA |
| --- |
| Rua Alfredo da Silva n.o 16 |
| P-2610-016 Amadora |

Euro-Labor SA

Rua Alfredo da Silva n.o 16

P-2610-016 Amadora

Bosporon

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

Romania

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

4 mg

Film-coated tablet

Oral

4 mg

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed Austria GmbH |
| --- |
| St. Peter Straße 25 |
| A-4020 Linz |

Nycomed Austria GmbH

St. Peter Straße 25

A-4020 Linz

Xefo

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

Spain

| Laboratorios Andromaco S.A. |
| --- |
| Doctor Zamenhof 36 |
| E-29027 Madrid |

Laboratorios Andromaco S.A.

Doctor Zamenhof 36

E-29027 Madrid

Acabel

4 mg

Film-coated tablet

Oral

4 mg

| Tedec Meiji Farma, S.A. |
| --- |
| Ctra. M-300 |
| Km 30,500 |
| E-28802 Alcalá de Henares, Madrid |

Tedec Meiji Farma, S.A.

Ctra. M-300

Km 30,500

E-28802 Alcalá de Henares, Madrid

Bosporon

4 mg

Film-coated tablet

Oral

4 mg

| Laboratorios Andromaco S.A. |
| --- |
| Doctor Zamenhof 36 |
| E-29027 Madrid |

Laboratorios Andromaco S.A.

Doctor Zamenhof 36

E-29027 Madrid

Acabel

8 mg

Film-coated tablet

Oral

8 mg

| Tedec Meiji Farma, S.A. |
| --- |
| Ctra. M-300 |
| Km 30,500 |
| E-28802 Alcalá de Henares, Madrid |

Tedec Meiji Farma, S.A.

Ctra. M-300

Km 30,500

E-28802 Alcalá de Henares, Madrid

Bosporon

8 mg

Film-coated tablet

Oral

8 mg

| Laboratorios Andromaco S.A. |
| --- |
| Doctor Zamenhof 36 |
| E-29027 Madrid |

Laboratorios Andromaco S.A.

Doctor Zamenhof 36

E-29027 Madrid

Acabel Rapid

8 mg

Film-coated tablet

Oral

8 mg

| Tedec Meiji Farma, S.A. |
| --- |
| Ctra. M-300 |
| Km 30,500 |
| E-28802 Alcalá de Henares, Madrid |

Tedec Meiji Farma, S.A.

Ctra. M-300

Km 30,500

E-28802 Alcalá de Henares, Madrid

Bosporon Rapid

8 mg

Film-coated tablet

Oral

8 mg

| Laboratorios Andromaco S.A. |
| --- |
| Doctor Zamenhof 36 |
| E-29027 Madrid |

Laboratorios Andromaco S.A.

Doctor Zamenhof 36

E-29027 Madrid

Acabel

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

Sweden

| Nycomed AB |
| --- |
| Tegeluddsvägen 17-21 |
| S-102 53 Stockholm |

Nycomed AB

Tegeluddsvägen 17-21

S-102 53 Stockholm

Xefo

4 mg

Film-coated tablet

Oral

4 mg

| Nycomed AB |
| --- |
| Tegeluddsvägen 17-21 |
| S-102 53 Stockholm |

Nycomed AB

Tegeluddsvägen 17-21

S-102 53 Stockholm

Xefo

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed AB |
| --- |
| Tegeluddsvägen 17-21 |
| S-102 53 Stockholm |

Nycomed AB

Tegeluddsvägen 17-21

S-102 53 Stockholm

Xefo Akut

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed AB |
| --- |
| Tegeluddsvägen 17-21 |
| S-102 53 Stockholm |

Nycomed AB

Tegeluddsvägen 17-21

S-102 53 Stockholm

Xefo

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

United Kingdom

| Nycomed UK Ltd |
| --- |
| The Magdalen Centre Oxford Science Park |
| OX4 4GA Oxford |
| United Kingdom |

Nycomed UK Ltd

The Magdalen Centre Oxford Science Park

OX4 4GA Oxford

United Kingdom

Xefo

4 mg

Film-coated tablet

Oral

4 mg

| Nycomed UK Ltd |
| --- |
| The Magdalen Centre Oxford Science Park |
| OX4 4GA Oxford |
| United Kingdom |

Nycomed UK Ltd

The Magdalen Centre Oxford Science Park

OX4 4GA Oxford

United Kingdom

Xefo

8 mg

Film-coated tablet

Oral

8 mg

| Nycomed UK Ltd |
| --- |
| The Magdalen Centre Oxford Science Park |
| OX4 4GA Oxford |
| United Kingdom |

Nycomed UK Ltd

The Magdalen Centre Oxford Science Park

OX4 4GA Oxford

United Kingdom

Xefo

4 mg/ml

Powder and solvent for solution for injection

Intravenous use/Intramuscular use

8 mg

---

ANNEX III

LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANT, MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES

| Member State | Marketing Authorisation Holder | Applicant | Invented name | Strength | Pharmaceutical Form | Route of administration |
| --- | --- | --- | --- | --- | --- | --- |
| Czech Republic | Zentiva, a.s. |
| U kabelovny 130 |
| Dolní Měcholupy |
| CZ-102 37 Praha 10 |

Member State

Marketing Authorisation Holder

Applicant

Invented name

Strength

Pharmaceutical Form

Route of administration

Czech Republic

Zentiva, a.s.

U kabelovny 130

Dolní Měcholupy

CZ-102 37 Praha 10

Alendros 70

70 mg

Tablet

Oral use

Estonia

| Zentiva, a.s. |
| --- |
| U kabelovny 130 |
| Dolní Měcholupy |
| CZ-102 37 Praha 10 |

Zentiva, a.s.

U kabelovny 130

Dolní Měcholupy

CZ-102 37 Praha 10

Alendros 70

70 mg

Tablet

Oral use

Hungary

| Zentiva, a.s. |
| --- |
| U kabelovny 130 |
| Dolní Měcholupy |
| CZ-102 37 Praha 10 |

Zentiva, a.s.

U kabelovny 130

Dolní Měcholupy

CZ-102 37 Praha 10

Alendros 70

70 mg

Tablet

Oral use

Latvia

| Zentiva, a.s. |
| --- |
| U kabelovny 130 |
| Dolní Měcholupy |
| CZ-102 37 Praha 10 |

Zentiva, a.s.

U kabelovny 130

Dolní Měcholupy

CZ-102 37 Praha 10

Alendros 70

70 mg

Tablet

Oral use

Lithuania

| Zentiva, a.s. |
| --- |
| U kabelovny 130 |
| Dolní Měcholupy |
| CZ-102 37 Praha 10 |

Zentiva, a.s.

U kabelovny 130

Dolní Měcholupy

CZ-102 37 Praha 10

Alendros 70

70 mg

Tablet

Oral use

Poland

| Zentiva, a.s. |
| --- |
| U kabelovny 130 |
| Dolní Měcholupy |
| CZ-102 37 Praha 10 |

Zentiva, a.s.

U kabelovny 130

Dolní Měcholupy

CZ-102 37 Praha 10

Alendros 70

70 mg

Tablet

Oral use

Slovakia

| Zentiva, a.s. |
| --- |
| U kabelovny 130 |
| Dolní Měcholupy |
| CZ-102 37 Praha 10 |

Zentiva, a.s.

U kabelovny 130

Dolní Měcholupy

CZ-102 37 Praha 10

Alendros 70

70 mg

Tablet

Oral use

---

V Announcements

ADMINISTRATIVE PROCEDURES

European Parliament

| 29.6.2007 | EN | Official Journal of the European Union | C 144/22 |
| --- | --- | --- | --- |

29.6.2007

EN

Official Journal of the European Union

C 144/22

---

CALL FOR PROPOSALS (No VIII-2008/01)

Grants to political parties at European level

(2007/C 144/08)

1.   OBJECTIVES

1.1   Background

Article 191 of the Treaty establishing the European Community says the political parties at European level are important factor for integration within the Union. They contribute to forming a European awareness and expressing the political will of the citizens of the Union. In this context, Regulation (EC) No 2004/2003 of the European Parliament and of the Council (1) lays down the regulations governing political parties at European level and the rules regarding their funding. The Regulation provides, in particular, for an annual grant from the European Parliament, in the form of an operating subsidy, to political parties which apply and which satisfy the conditions laid down in the Regulation.

1.2   Objective of the call for proposals

Under Article 2 of the Decision of the Bureau of the European Parliament of 29 March 2004 laying down the procedures for implementing Regulation (EC) No 2004/2003 (2), ‘The European Parliament shall publish each year, before the end of the first half of the year, a call for proposals with a view to the awarding of grants to fund political parties at European level.’ This call for proposals relates to grant applications for the financial year 2008 covering the period of activity from 1.1.2008 to 31.12.2008.

2.   CRITERIA AND SUPPORTING DOCUMENTS

2.1.   Admissibility

Applications will not be admissible unless they are submitted in writing on the grant application form in Annex 1 of the above Decision of the Bureau of the European Parliament of 29 March 2004, forwarded to the President of the European Parliament by the closing date and meet the conditions for the submission of applications set out below.

2.2.   Eligibility criteria

In order to be eligible for a grant, a political party at European level must satisfy the conditions laid down in Article 3 of Regulation (EC) No 2004/2003, i.e.:

| (a) | it must have legal personality in the Member State in which its seat is located; |
| --- | --- |

(a)

it must have legal personality in the Member State in which its seat is located;

| (b) | it must be represented, in at least one quarter of Member States, by Members of the European Parliament or in the national Parliaments or regional Parliaments or in the regional assemblies, or it must have received, in at least one quarter of the Member States, at least three per cent of the votes cast in each of those Member States at the most recent European Parliament elections; |
| --- | --- |

(b)

it must be represented, in at least one quarter of Member States, by Members of the European Parliament or in the national Parliaments or regional Parliaments or in the regional assemblies, or it must have received, in at least one quarter of the Member States, at least three per cent of the votes cast in each of those Member States at the most recent European Parliament elections;

| (c) | it must observe, in particular in its programme and in its activities, the principles on which the European Union is founded, namely the principles of liberty, democracy, respect for human rights and fundamental freedoms, and the rule of law; |
| --- | --- |

(c)

it must observe, in particular in its programme and in its activities, the principles on which the European Union is founded, namely the principles of liberty, democracy, respect for human rights and fundamental freedoms, and the rule of law;

| (d) | it must have participated in elections to the European Parliament, or have expressed the intention to do so. |
| --- | --- |

(d)

it must have participated in elections to the European Parliament, or have expressed the intention to do so.

2.3   Exclusion criteria

Applicants must also certify that they do not find themselves in any of the circumstances described in Articles 93 and 94 of the Council Regulation (EC, Euratom) No 1605/2002 of 25 June 2002 on the Financial Regulation applicable to the general budget of the European Communities (3).

2.4.   Selection criteria

Applicants must provide evidence that they possess the legal and financial viability required to carry out the programme of activities set out in the application for funding and that they have the technical capability and management skills needed to carry out successfully the programme activities for which they are applying for a grant.

2.5   Award criteria

In accordance with Article 10 of Regulation (EC) No 2004/2003, the available appropriations for the financial year 2008 will be distributed as follows among the political parties at European level which have obtained a positive decision on their application for funding on the basis of the admissibility, eligibility, exclusion and selection criteria:

| (a) | 15 % will be distributed in equal shares; |
| --- | --- |

(a)

15 % will be distributed in equal shares;

| (b) | 85 % will be distributed among those which have elected members in the European Parliament, in proportion to the number of elected members. |
| --- | --- |

(b)

85 % will be distributed among those which have elected members in the European Parliament, in proportion to the number of elected members.

2.6   Supporting documents

For the purpose of assessing the above criteria, applicants must provide the following supporting documents:

| (a) | Original covering letter |
| --- | --- |

(a)

Original covering letter

| (b) | Application form in Annex 1 of the Decision of the Bureau of the European Parliament of 29 March 2004 duly completed and signed (including the written solemn declaration) |
| --- | --- |

(b)

Application form in Annex 1 of the Decision of the Bureau of the European Parliament of 29 March 2004 duly completed and signed (including the written solemn declaration)

| (c) | Statutes of the political party |
| --- | --- |

(c)

Statutes of the political party

| (d) | Official certificate of registration |
| --- | --- |

(d)

Official certificate of registration

| (e) | Recent proof of existence of the political party |
| --- | --- |

(e)

Recent proof of existence of the political party

| (f) | List of the directors/members of the Management Board (names and forenames, titles or functions within the applicant party) |
| --- | --- |

(f)

List of the directors/members of the Management Board (names and forenames, titles or functions within the applicant party)

| (g) | Documents certifying that the applicant meets the conditions laid down in Articles 3 (b), (c) and (d) and 10(1)(b) (4) of Regulation (EC) No 2004/2003 (or declaration that there have been no changes to documents already forwarded) |
| --- | --- |

(g)

Documents certifying that the applicant meets the conditions laid down in Articles 3 (b), (c) and (d) and 10(1)(b) (4) of Regulation (EC) No 2004/2003 (or declaration that there have been no changes to documents already forwarded)

| (h) | Programme of the political party |
| --- | --- |

(h)

Programme of the political party

| (i) | Comprehensive financial statement for 2006 certified by an external auditing body (5) |
| --- | --- |

(i)

Comprehensive financial statement for 2006 certified by an external auditing body (5)

| (j) | Provisional operating budget for the period concerned (1.1.2008 to 31.12.2008) indicating expenditure eligible for funding from the Community budget. |
| --- | --- |

(j)

Provisional operating budget for the period concerned (1.1.2008 to 31.12.2008) indicating expenditure eligible for funding from the Community budget.

3.   COMMUNITY FUNDING

The budget for the financial year 2008 is estimated at a total of EUR 10 645 000, subject to approval by the budgetary authority.

The maximum amount paid to the beneficiary by the European Parliament may not exceed 75 % of the eligible operating costs of political parties at European level. The burden of proof shall lie with the political party concerned.

Community funding shall take the form of an operating grant as provided for by the Financial Regulation and the Commission Regulation (EC, Euratom) No 2342/2002 of 23 December 2002 laying down detailed rules for the implementation of Council Regulation (EC, Euratom) No 1605/2002 on the Financial Regulation applicable to the general budget of the European Communities (6). The arrangements for paying the grant and the obligations governing its use will be set out in a grant award agreement, a specimen of which appears in Annex 2 to the Decision of the Bureau of the European Parliament of 29 March 2004.

4.   PROCEDURE

4.1   Closing date and submission of applications

The closing date for forwarding the applications is 14.11.2007. Applications forwarded after that date will not be considered.

Applications must:

| — | be made on the grant application form; |
| --- | --- |

—

be made on the grant application form;

| — | be signed, without fail, by the applicant or his duly authorised agent; |
| --- | --- |

—

be signed, without fail, by the applicant or his duly authorised agent;

| — | be submitted under double cover; the two envelopes must be sealed. In addition to the address of the recipient department as given in the call for proposals, the inner envelope must bear the following:

  ‘Call for proposals — 2008 grants to political parties at European level

  NOT TO BE OPENED BY THE MAIL SERVICE
  OR BY ANY OTHER UNAUTHORISED PERSON’

  If self-adhesive envelopes are used, they must be sealed with adhesive tape with the signature of the sender affixed across it. The signature of the sender shall be deemed to comprise not only his hand-written signature, but also his organisation's stamp; |
| --- | --- |

—

be submitted under double cover; the two envelopes must be sealed. In addition to the address of the recipient department as given in the call for proposals, the inner envelope must bear the following:

‘Call for proposals — 2008 grants to political parties at European level

NOT TO BE OPENED BY THE MAIL SERVICE

OR BY ANY OTHER UNAUTHORISED PERSON’

If self-adhesive envelopes are used, they must be sealed with adhesive tape with the signature of the sender affixed across it. The signature of the sender shall be deemed to comprise not only his hand-written signature, but also his organisation's stamp;

| — | be forwarded at the latest on the closing date laid down in the call for proposals either by registered mail, as evidenced by the postmark or by courier service as evidenced by the date of the deposit slip,
  The outer envelope must be addressed to:





  EUROPEAN PARLIAMENT |
| --- | --- |
| Mail Service |
| KAD 00D008 |
| L-2929 Luxembourg |

—

be forwarded at the latest on the closing date laid down in the call for proposals either by registered mail, as evidenced by the postmark or by courier service as evidenced by the date of the deposit slip,

The outer envelope must be addressed to:

EUROPEAN PARLIAMENT

Mail Service

KAD 00D008

L-2929 Luxembourg

This envelope must also show the sender's address.

The inner envelope must be addressed to:

| President of the European Parliament |
| --- |
| via Mr Vanhaeren, Director-General of Finance |
| SCH 05B031 |
| L-2929 Luxembourg |

President of the European Parliament

via Mr Vanhaeren, Director-General of Finance

SCH 05B031

L-2929 Luxembourg

4.2   Timetable for implementing the programme of activities

The eligible period for cofinancing of operating expenditure of political parties at European level in 2008 runs from 1.1.2008 until 31.12.2008.

4.3   Award procedure and timetable

The following procedure and timetable will apply to the awarding of grants to political parties at European level:

| (a) | Forwarding of the application to the European Parliament (no later than 14.11.2007) |
| --- | --- |

(a)

Forwarding of the application to the European Parliament (no later than 14.11.2007)

| (b) | Consideration and selection by the European Parliament's departments. Only the applications deemed admissible will be examined on the basis of the eligibility, exclusion and selection criteria set out in the call for proposals. |
| --- | --- |

(b)

Consideration and selection by the European Parliament's departments. Only the applications deemed admissible will be examined on the basis of the eligibility, exclusion and selection criteria set out in the call for proposals.

| (c) | Adoption of the final decision by the Bureau of the European Parliament (before 15.2.2008) and notification of applicants. |
| --- | --- |

(c)

Adoption of the final decision by the Bureau of the European Parliament (before 15.2.2008) and notification of applicants.

| (d) | Signature of grant award agreement (within 30 days following the Bureau decision) |
| --- | --- |

(d)

Signature of grant award agreement (within 30 days following the Bureau decision)

| (e) | Payment of an advance of 80 % (within 15 days following the signing of the agreement). |
| --- | --- |

(e)

Payment of an advance of 80 % (within 15 days following the signing of the agreement).

4.4   Further information

The following texts are available on the European Parliament's Internet site at the following address:

http://www.europarl.europa.eu/tenders/invitations.htm:

| (a) | Regulation (EC) No 2004/2003 of the European Parliament and of the Council of 4 November 2003 on the regulations governing political parties at European level and the rules regarding their funding; |
| --- | --- |

(a)

Regulation (EC) No 2004/2003 of the European Parliament and of the Council of 4 November 2003 on the regulations governing political parties at European level and the rules regarding their funding;

| (b) | Decision of the Bureau of the European Parliament of 29 March 2004 laying down procedures for implementing Regulation (EC) No 2004/2003 of the European Parliament and of the Council on the regulations governing political parties at European level and the rules regarding their funding; |
| --- | --- |

(b)

Decision of the Bureau of the European Parliament of 29 March 2004 laying down procedures for implementing Regulation (EC) No 2004/2003 of the European Parliament and of the Council on the regulations governing political parties at European level and the rules regarding their funding;

| (c) | Grant application form; |
| --- | --- |

(c)

Grant application form;

| (d) | Specimen agreement. |
| --- | --- |

(d)

Specimen agreement.

Any questions relating to this call for proposals with a view to the awarding of grants should be sent by e-mail, quoting the publication reference, to the following address:

Helmut.Betz@europarl.europa.eu

---

(1)  OJ L 297, 15.11.2003, p. 1

1

(2)  OJ C 155, 12.6.2004, p. 1. Decision as amended by the Bureau on 1 February 2006 (OJ C 150, 28.6.2006, p. 9).

2

(3)  OJ L 248, 16.9.2002, p. 1. Regulation as last amended by Regulation (EC, Euratom) No 1995/2006 (OJ L 390, 30.12.2006, p. 1).

3

(4)  Including the lists of elected persons referred to in Articles 3(b), first subparagraph, and 10(1)(b).

4

(5)  Unless the political party at European level was established during the current year.

5

(6)  OJ L 357, 31.12.2002, p. 1. Regulation as amended by Regulation (EC, Euratom) No 478/2007 (OJ L 111, 28.4.2007, p. 13).

6

---

PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMPETITION POLICY

Commission

| 29.6.2007 | EN | Official Journal of the European Union | C 144/25 |
| --- | --- | --- | --- |

29.6.2007

EN

Official Journal of the European Union

C 144/25

---

Prior notification of a concentration

(Case COMP/M.4688 — Nestlé/Gerber)

(Text with EEA relevance)

(2007/C 144/09)

| 1. | On 22 June 2007, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Nestlé S.A. (‘Nestlé’, Switzerland) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the Gerber business (‘Gerber, US’), belonging to Novartis AG (‘Novartis’, Switzerland), by way of purchase of shares and assets. |
| --- | --- |

1.

On 22 June 2007, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Nestlé S.A. (‘Nestlé’, Switzerland) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the Gerber business (‘Gerber, US’), belonging to Novartis AG (‘Novartis’, Switzerland), by way of purchase of shares and assets.

| 2. | The business activities of the undertakings concerned are:






  — | for Nestlé: the production, marketing and sale of a large variety of food and beverage products, including baby food; |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for Nestlé: the production, marketing and sale of a large variety of food and beverage products, including baby food;

| — | for Gerber: production, marketing and sale of baby food, baby care and baby accessories; |
| --- | --- |

—

for Gerber: production, marketing and sale of baby food, baby care and baby accessories;

| — | for Novartis: a major healthcare products company. |
| --- | --- |

—

for Novartis: a major healthcare products company.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4688 — Nestlé/Gerber, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| B-1049 Bruxelles/Brussel |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4688 — Nestlé/Gerber, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

B-1049 Bruxelles/Brussel

---

(1)  OJ L 24, 29.1.2004, p. 1.

---